NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 262 filers reported holding NEKTAR THERAPEUTICS in Q2 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,382,948 | -39.9% | 5,679,900 | -41.9% | 0.00% | 0.0% |
Q2 2023 | $5,624,969 | +169.9% | 9,779,152 | +229.8% | 0.00% | – |
Q1 2023 | $2,084,429 | -51.5% | 2,965,470 | +55.9% | 0.00% | -100.0% |
Q4 2022 | $4,300,052 | +6.5% | 1,902,678 | +50.8% | 0.00% | 0.0% |
Q3 2022 | $4,037,000 | +77.2% | 1,261,562 | +110.5% | 0.00% | – |
Q2 2022 | $2,278,000 | -80.5% | 599,350 | -72.3% | 0.00% | -100.0% |
Q1 2022 | $11,682,000 | +140.8% | 2,167,394 | +503.7% | 0.00% | +100.0% |
Q4 2021 | $4,851,000 | -9.1% | 359,031 | +20.8% | 0.00% | – |
Q3 2021 | $5,338,000 | -5.6% | 297,237 | -9.8% | 0.00% | -100.0% |
Q2 2021 | $5,656,000 | -10.1% | 329,551 | +4.8% | 0.00% | -50.0% |
Q1 2021 | $6,289,000 | -1.2% | 314,447 | -16.1% | 0.00% | +100.0% |
Q4 2020 | $6,368,000 | -38.8% | 374,613 | -40.3% | 0.00% | -66.7% |
Q3 2020 | $10,412,000 | -51.0% | 627,601 | -31.6% | 0.00% | -57.1% |
Q2 2020 | $21,248,000 | +29.6% | 917,427 | -0.1% | 0.01% | 0.0% |
Q1 2020 | $16,390,000 | +16.5% | 918,180 | +40.9% | 0.01% | +16.7% |
Q4 2019 | $14,070,000 | +62.0% | 651,845 | +36.7% | 0.01% | +100.0% |
Q3 2019 | $8,687,000 | -33.1% | 476,958 | +30.8% | 0.00% | -50.0% |
Q2 2019 | $12,976,000 | -29.2% | 364,713 | -33.1% | 0.01% | -33.3% |
Q1 2019 | $18,332,000 | -36.6% | 545,568 | -38.0% | 0.01% | -40.0% |
Q4 2018 | $28,932,000 | +9.5% | 880,180 | +103.2% | 0.02% | +36.4% |
Q3 2018 | $26,410,000 | -37.4% | 433,236 | -49.8% | 0.01% | -45.0% |
Q2 2018 | $42,174,000 | +200.5% | 863,697 | +553.9% | 0.02% | +185.7% |
Q1 2018 | $14,036,000 | +45.0% | 132,085 | -18.5% | 0.01% | +16.7% |
Q4 2017 | $9,683,000 | +124.9% | 162,126 | -9.6% | 0.01% | +100.0% |
Q3 2017 | $4,305,000 | +26.1% | 179,343 | +2.7% | 0.00% | +50.0% |
Q2 2017 | $3,413,000 | +35.5% | 174,601 | +62.8% | 0.00% | -33.3% |
Q1 2017 | $2,518,000 | +300.3% | 107,261 | +109.4% | 0.00% | – |
Q4 2016 | $629,000 | -9.1% | 51,226 | +27.0% | 0.00% | – |
Q3 2016 | $692,000 | +408.8% | 40,320 | +270.5% | 0.00% | – |
Q2 2015 | $136,000 | -70.1% | 10,884 | -73.7% | 0.00% | – |
Q1 2015 | $455,000 | +506.7% | 41,414 | +761.5% | 0.00% | – |
Q4 2014 | $75,000 | -98.4% | 4,807 | -98.7% | 0.00% | -100.0% |
Q3 2014 | $4,552,000 | +159.5% | 377,144 | +175.7% | 0.01% | +150.0% |
Q2 2014 | $1,754,000 | +221.2% | 136,816 | +184.5% | 0.00% | +100.0% |
Q4 2013 | $546,000 | -61.4% | 48,096 | -60.7% | 0.00% | -50.0% |
Q2 2013 | $1,413,000 | – | 122,367 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |